Multicentric randomized phase III study comparing high doses of chemotherapy with rituximab followed by auto-transplant HPC versus CHOP plus rituximab as first line therapy in high risk patients with DLBCL non-Hodgkin's lymphomas

Trial Profile

Multicentric randomized phase III study comparing high doses of chemotherapy with rituximab followed by auto-transplant HPC versus CHOP plus rituximab as first line therapy in high risk patients with DLBCL non-Hodgkin's lymphomas

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Melphalan; Mitoxantrone; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 10 Dec 2012 Primary endpoint 'Event-free-survival-rate' has not been met.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top